The DNA sequencing pioneer promised a $1,000 human genome by early 2019. The price isn't so important, but the technology upgrades will prove critical.
News & Analysis: Pacific Biosciences of California
Abandoning the proposed deal would have a seismic effect on the future of DNA sequencing, but it's not all bad news for investors.
Bad news on several different fronts held these stocks back.
Trade investigations and a stumbling patent portfolio have investors growing anxious about the pending acquisition by Illumina.
The DNA sequencing leader moved forward in its quest to acquire Pacific Biosciences -- and Wall Street approved.
The United Kingdom's Competition and Markets Authority has opened an investigation into the acquisition. What happens now?
The $1.2 billion acquisition will combine the two leading DNA sequencing technology platforms, but the battle for the future of DNA sequencing is just getting started.
A 71% premium for a less-successful competitor may seem excessive, but timing is everything.
Find out which of these stocks got a buyout bid.
A $1.2 billion acquisition of the gene-sequencing company sends its shares into orbit.